ON01910NA ENHANCING ACTIVITY OF CHEMOTHERAPEUTIC AGENT IN DRUG-RESISTANT TUMOURS

摘要

FIELD: medicine, pharmaceutics.;SUBSTANCE: there are offered: a pharmaceutical composition containing a mitotic disruptor/a polo-like kinase (Plk) biochemical path inhibitor, particularly ON01910, ON01910-Na or Plkl-targeted siRNA, and a chemotherapeutic agent representing a nucleotide analogue in an effective amount, as well as an acceptable carrier to be used as a drug to prevent developing resistance to the chemotherapeutic agent representing the nucleotide analogue in an individual suffering cancer, or to be used as a drug for treating cancer resistant to the chemotherapeutic agent representing the nucleotide analogue in a patient in need thereof, and the same intended use of the mitotic disruptor/the polo-like kinase (Plk) biochemical path inhibitor, particularly ON01910, ON01910-Na or Plkl-targeted siRNA, and the chemotherapeutic agent representing the nucleotide analogue.;EFFECT: what is shown is a synergic effect of the declared combination and negotiation or prevention of developing resistance to the chemotherapeutic agent.;15 cl, 3 dwg, 5 ex